Phase 1/2 × Sarcoma × Dermatologic × Clear all
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
NCT04140526 2025-05-23

PRESERVE-001

OncoC4, Inc.

Phase 1/2 Active not recruiting
733 enrolled
NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

Phase 1/2 Completed
34 enrolled 14 charts
NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

Phase 1/2 Unknown
314 enrolled